株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

中枢神経系 (CNS) リンパ腫の世界市場:予後の種類・診断の種類・治療の種類・用途別の将来予測

CNS Lymphoma Market - Forecast (2020 - 2025)

発行 IndustryARC 商品コード 416591
出版日 ページ情報 英文 104 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.95円で換算しております。
中枢神経系 (CNS) リンパ腫の世界市場:予後の種類・診断の種類・治療の種類・用途別の将来予測 CNS Lymphoma Market - Forecast (2020 - 2025)
出版日: 2020年03月11日 ページ情報: 英文 104 Pages
概要

当レポートでは、世界の中枢神経系 (CNS) リンパ腫の市場について分析し、全体的な市場構造や背景事情、主な市場促進・抑制要因、予後/診断/治療の種類別および地域別の市場動向見通し、市場競争の情勢、昨今の資本取引・戦略展開の動き、主要企業のプロファイルなどについて調査しております。

第1章 市場概要

第2章 エグゼクティブ・サマリー

第3章 中枢神経系 (CNS) リンパ腫市場:市場環境

  • 市場シェア分析
  • 競争分析
    • エンドユーザーのプロファイル
    • 特許分析
    • 上位5社の財務分析

第4章 CNSリンパ腫市場:市場への影響要因

  • 市場成長促進要因
  • 市場抑制要因
  • 市場の課題
  • 市場の求心力:ポーターのファイブフォース分析

第5章 CNSリンパ腫市場:戦略分析

  • バリューチェーン分析
  • 価格動向の分析
  • 市場機会の分析
  • 製品ライフサイクルの分析
  • サプライヤー/流通業者

第6章 CNSリンパ腫市場:予後の種類別

  • 免疫応答性
  • AIDS (後天性免疫不全症候群)

第7章 CNSリンパ腫市場:診断の種類別

  • 腰椎穿刺/脳脊髄液 (CSF) の病理解析
  • 脳生検サンプル採取
  • MRI (核磁気共鳴画像)
  • CT (コンピューター断層撮影) スキャン
  • 定位生検
  • 全血球計算 (CBC)
  • その他

第8章 CNSリンパ腫市場:治療の種類別

  • 放射線治療
  • 化学療法
  • ステロイド治療
  • 大量化学療法 (幹細胞移植付き)
  • 標的療法
  • その他

第9章 CNSリンパ腫市場:地域別

  • 北米 (米国、カナダなど)
  • 欧州 (英国、ドイツ、フランス、スペイン、イタリアなど)
  • アジア太平洋地域 (中国、インド、日本、オーストラリアなど)
  • ラテンアメリカ (ブラジル、アルゼンチン、メキシコなど)
  • 他の国々 (RoW:中東、アフリカ)

第10章 CNSリンパ腫市場:市場のエントロピー (市場変化の方向性)

  • 新製品の発売
  • 企業合併・買収 (M&A)、事業提携・協力、合弁事業 (JV)

第11章 企業プロファイル (概要、財務分析、主要製品・サービス、近年の動向、競合企業、顧客)

  • Brainstrust
  • Brain and Spine Foundation
  • Headway
  • Royal National Institute for the Blind (RNIB)
  • Carers UK
  • Cancer Research UK
  • American Brain Tumor Association
  • Leukaemia Foundation
  • Macmillan Cancer Support
  • Center for Lymphoid Malignancies

第12章 付録

目次
Product Code: HCR 0124

Central Nervous System (CNS) Lymphoma or microglioma is a disease in which cancer cells are formed in the lymph tissue of the brain or spinal cord. This is observed primarily in patients with very weak immune systems, patients suffering from immunosuppression, and AIDS patients. Patients who have undergone recent kidney or other organ transplants are also at a high risk of having CNS lymphoma due to their low count of T-Cells or low level of immunity. The major symptoms of this disease include headaches, memory problem, drowsiness, seizures, nausea, vomiting, personality changes, throat infection, body weakness, and sometimes, even hearing loss and double vision. This disease may occur in all age groups; however, it is mostly noticed in people in the 50+ age group. The global central nervous system lymphoma market is estimated to surpass $1,127m by 2023, growing at an estimated CAGR of 6.65% from 2018 to 2023. The North America region is the largest market for CNS lymphoma.

CNS Lymphoma Market Outlook

The report covers the major diagnosis methods including lumber puncture, pathological analysis of cerebrospinal fluid (CSF), brain biopsy sampling, magnetic resonance imaging (MRI), computed topography (CT) scan, stereostatic biopsy, and complete blood count. The market is further categorized by prognosis types, which include Immunocompetent and AIDS. Based on treatment types, the market is segmented into radiation therapy, chemotherapy, steroid therapy, targeted therapy, and others.

CNS Lymphoma Market Growth Drivers

The market is expected to be majorly driven by the rising prevalence of primary CNS lymphoma, increasing awareness regarding the advanced technologies in the market, and rising governmental spending on healthcare. The demand for diagnostic methods is on the surge; thus, propelling the demand for CNS lymphoma treatment across the regions.

CNS Lymphoma Market Challenges

Stringent regulations imposed on drugs by the regulatory bodies coupled with the rising R&D costs pose major challenges for the CNS lymphoma market. Owing to the intake of drug, chances of occurrence of side effects such as fatigue, gastrointestinal complication, graft versus host disease, and late effects of cancer survivors will negatively impact the growth of the market.

CNS Lymphoma Market

CNS Lymphoma Assembly Market Research Scope

The base year of the study is 2017, with forecast done up to 2023. The study presents a thorough analysis of the competitive landscape, taking into account the market shares of the leading companies. It also provides information on unit shipments. These provide the key market participants with the necessary business intelligence and help them understand the future of the CNS lymphoma market. The assessment includes the forecast, an overview of the competitive structure, the market shares of the competitors, as well as the market trends, market demands, market drivers, market challenges, and product analysis. The market drivers and restraints have been assessed to fathom their impact over the forecast period. This report further identifies the key opportunities for growth while also detailing the key challenges and possible threats. The key areas of focus include the types of prognosis and diagnosis in the CNS Lymphoma market, and their treatment methods.

CNS Lymphoma Market Report: Industry Coverage

Prognosis in CNS Lymphoma Market: Immunocompetent and AIDS

Diagnosis in CNS Lymphoma Market: Lumbar Puncture/Pathological Analysis of Cerebrospinal Fluid (CSF), Brain Biopsy Sampling and Stereotactic Biopsy, Magnetic Resonance Imaging (MRI), Computed Topography (CT scan), Complete Blood Count, and Others

Treatment in CNS Lymphoma Market: Radiation Therapy, Chemotherapy, Steroid Therapy, and Others

The CNS lymphoma Market report also analyzes the major geographic regions for the market as well as the major countries for the market in these regions. The regions and countries covered in the study include:

North America: The U.S., Canada, Mexico

Europe: The U.K., Germany, Italy, France, Spain, Rest of Europe

APAC: China, Japan, Australia & New Zealand, South Korea, India, Rest of APAC

RoW: The Middle East, Africa, South America

CNS Lymphoma Market Key Players Perspective

Some of the key players mentioned in this report are Amgen Inc., Celegene Corp., Cipla Inc., Dr. Reddy's Laboratories, F. Hoffmann-La Roche Ltd., Fresenius SE & CO. KGAA, Gilead Science, Inc., Johnson & Johnson, Merck & CO., Inc., and Sanofi S.A.

CNS Lymphoma Market Trends

Increased investments in healthcare, and research and development

Growing prevalence of primary CNS lymphoma, and increasing awareness about advanced technologies in the market

Advancements in MRI and CT scan technology coupled with increasing healthcare expenditure are driving the growth of the market.

Diagnosis methods such as Magnetic Resonance Imaging (MRI) accounted for the major share of the total market in 2017. As per IndustryARC analysis, the chemotherapy segment will generate healthy revenue by 2023.

1. CNS Lymphoma Market - Overview

  • 1.1. Definitions and Scope

2. CNS Lymphoma Market - Executive summary

  • 2.1. Market Revenue, Market Size and Key Trends by Company
  • 2.2. Key Trends by type of Application
  • 2.3. Key Trends segmented by Geography

3. CNS Lymphoma Market

  • 3.1. Comparative analysis
    • 3.1.1. Product Benchmarking - Top 10 companies
    • 3.1.2. Top 5 Financials Analysis
    • 3.1.3. Market Value split by Top 10 companies
    • 3.1.4. Patent Analysis - Top 10 companies
    • 3.1.5. Pricing Analysis

4. CNS Lymphoma Market Forces

  • 4.1. Drivers
  • 4.2. Constraints
  • 4.3. Challenges
  • 4.4. Porters five force model
    • 4.4.1. Bargaining power of suppliers
    • 4.4.2. Bargaining powers of customers
    • 4.4.3. Threat of new entrants
    • 4.4.4. Rivalry among existing players
    • 4.4.5. Threat of substitutes

5. CNS Lymphoma Market -Strategic analysis

  • 5.1. Value chain analysis
  • 5.2. Opportunities analysis
  • 5.3. Product life cycle
  • 5.4. Suppliers and distributors Market Share

6. CNS Lymphoma Market - By Prognosis Type (Market Size -$Million / $Billion)

  • 6.1. Market Size and Market Share Analysis
  • 6.2. Application Revenue and Trend Research
  • 6.3. Product Segment Analysis
    • 6.3.1. Immunocompetent
    • 6.3.2. AIDS

7. CNS Lymphoma Market - By Type of Diagnosis (Market Size -$Million / $Billion)

  • 7.1. Introduction
  • 7.2. Lumbar Puncture/Pathological Analysis of cerebrospinal fluid (CSF)
  • 7.3. Brain biopsy sampling
  • 7.4. MRI (Magnetic Resonance Imaging)
  • 7.5. CT Scan (Computed Tomography)
  • 7.6. Stereotactic Biopsy
  • 7.7. Complete Blood Count
  • 7.8. Others

8. CNS Lymphoma Market - By Type of Treatment (Market Size -$Million / $Billion)

  • 8.1. Introduction
  • 8.2. Radiation Therapy
  • 8.3. Chemotherapy
  • 8.4. Steroid Therapy
  • 8.5. Targeted Therapy
  • 8.6. Others

9. CNS Lymphoma - By Geography (Market Size -$Million / $Billion)

  • 9.1. CNS Lymphoma Market - North America Segment Research
  • 9.2. North America Market Research (Million / $Billion)
    • 9.2.1. Segment type Size and Market Size Analysis
    • 9.2.2. Revenue and Trends
    • 9.2.3. Application Revenue and Trends by type of Application
    • 9.2.4. Company Revenue and Product Analysis
    • 9.2.5. North America Product type and Application Market Size
      • 9.2.5.1. U.S.
      • 9.2.5.2. Canada
      • 9.2.5.3. Mexico
      • 9.2.5.4. Rest of North America
  • 9.3. CNS Lymphoma - South America Segment Research
  • 9.4. South America Market Research (Market Size -$Million / $Billion)
    • 9.4.1. Segment type Size and Market Size Analysis
    • 9.4.2. Revenue and Trends
    • 9.4.3. Application Revenue and Trends by type of Application
    • 9.4.4. Company Revenue and Product Analysis
    • 9.4.5. South America Product type and Application Market Size
      • 9.4.5.1. Brazil
      • 9.4.5.2. Venezuela
      • 9.4.5.3. Argentina
      • 9.4.5.4. Ecuador
      • 9.4.5.5. Peru
      • 9.4.5.6. Colombia
      • 9.4.5.7. Costa Rica
      • 9.4.5.8. Rest of South America
  • 9.5. CNS Lymphoma - Europe Segment Research
  • 9.6. Europe Market Research (Market Size -$Million / $Billion)
    • 9.6.1. Segment type Size and Market Size Analysis
    • 9.6.2. Revenue and Trends
    • 9.6.3. Application Revenue and Trends by type of Application
    • 9.6.4. Company Revenue and Product Analysis
    • 9.6.5. Europe Segment Product type and Application Market Size
      • 9.6.5.1. U.K
      • 9.6.5.2. Germany
      • 9.6.5.3. Italy
      • 9.6.5.4. France
      • 9.6.5.5. Netherlands
      • 9.6.5.6. Belgium
      • 9.6.5.7. Spain
      • 9.6.5.8. Denmark
      • 9.6.5.9. Rest of Europe
  • 9.7. CNS Lymphoma - APAC Segment Research
  • 9.8. APAC Market Research (Market Size -$Million / $Billion)
    • 9.8.1. Segment type Size and Market Size Analysis
    • 9.8.2. Revenue and Trends
    • 9.8.3. Application Revenue and Trends by type of Application
    • 9.8.4. Company Revenue and Product Analysis
    • 9.8.5. APAC Segment - Product type and Application Market Size
      • 9.8.5.1. China
      • 9.8.5.2. Australia
      • 9.8.5.3. Japan
      • 9.8.5.4. South Korea
      • 9.8.5.5. India
      • 9.8.5.6. Taiwan
      • 9.8.5.7. Malaysia

10. CNS Lymphoma Market - Entropy

  • 10.1. New product launches
  • 10.2. M&A's, collaborations, JVs and partnerships

11. CNS Lymphoma Market Company Analysis

  • 11.1. Market Share, Company Revenue, Products, M&A, Developments
  • 11.2. Amgen Inc.
  • 11.3. Celegene Corp.
  • 11.4. Cipla Inc.
  • 11.5. Dr. Reddy's Laboratories
  • 11.6. F. Hoffmann-La Roche Ltd.
  • 11.7. Fresenius SE & CO. KGAA
  • 11.8. Gilead Science Inc.
  • 11.9. Johnson & Johnson
  • 11.10. Merck & CO., Inc.,
  • 11.11. Company 10
  • 11.12. Company 11
  • 11.13. Company 12 and more

"*Financials would be provided on a best efforts basis for private companies"

12. CNS Lymphoma Market -Appendix

  • 12.1. Abbreviations
  • 12.2. Sources